CAR T-Cell Therapy, an immunotherapy, is a novel therapy that programs a patient’s immune system to recognize and fight cancer. The immune system is responsible for ridding the body of abnormal cells that are foreign (like cancer) or infected. T-lymphocytes (T-Cells) are a type of cell responsible for killing abnormal cells. During the CAR T-Cell treatment process, T-Cells are drawn from a patient's blood and genetically modified to recognize the patient’s cancer cells when reinfused.
Here’s how it works:
- First, a patient’s white blood cells are collected through a process called apheresis.
- Then, the T-Cells are isolated from other blood cells.
- T-Cells are then modified in a special facility to program them to recognize the cancer cells, what can be thought of as “fighter” T-Cells.
- Lastly, the new “fighter” T-Cells are reinfused into the patient to target and kill the cancer.
CAR T-Cell Therapy Clinical Trials
CAR T-Cell Therapy is an exciting new therapy that has been in research trials over the last few years. These types of treatments will be introduced gradually, and are available only at centers where doctors and nurses have been specially-trained and meet Foundation for Accreditation of Cellular Therapy (FACT) accreditation standards. Texas Transplant Institute at Methodist Hospital, a member of the Sarah Cannon Blood Cancer Network, the Cancer Institute of HCA Healthcare, has offered research options since 2015 and has clinical trials open in:
- Mantle Cell NHL
To learn more about clinical trials, CAR T-Cell Therapy (a type of immunotherapy), and potential treatment options for you, visit MethodistBMT.com or contact: